Nivolumab May Work as First-Line NSCLC Therapy.
The first trial of nivolumab as a first-line therapy for non-small cell lung cancer suggests that the drug can improve survival. Adding some platinum-doublet chemotherapy combinations did not further increase this effect, although the median overall survival wasn't reached for paclitaxel and carboplatin. Adding chemotherapy may increase the immunotherapy's toxicity.